Studying patient similarity and cognitive change over time, with Alzheimer's disease as the focus. SOMA combines longitudinal research inputs with federated matching and privacy-preserving methods.
SOMA is an Alzheimer's research initiative by Curadai. The work uses retrospective research cohorts to investigate patient representations, cognitive trajectories, and privacy. It is a research foundation, not a clinical diagnostic service. The work is conducted independently of the institutions that contributed the research data.
Alzheimer's researchers need to compare cognitive change across participants and time. Fragmented records, privacy requirements, and incomplete measurements make it difficult to identify participants with similar trajectories.
Patient records siloed across institutions with incompatible EHR systems and clinical vocabularies.
Research permissions and privacy requirements shape how sensitive participant data can be accessed and shared.
Existing approaches treat patients as frozen in time, losing critical trajectory and progression information.
Alzheimer's research visits may have cognitive scores without every scan, genetic measure, or biomarker.
Seven research capabilities connect the participant's measurements, cognitive history, and potential peers. The scope is retrospective Alzheimer's cohort research; clinical usefulness requires further independent evaluation.
The Alzheimer's work combines cognitive assessments, brain imaging, genetics, and biomarkers into patient representations. Evaluation examines whether nearby representations reflect meaningful differences between cognitively normal participants, mild cognitive impairment, and Alzheimer's dementia.
SOMA studies patient similarity across research sites while keeping source records local. The Alzheimer's privacy experiments examine protected population summaries and the effect of privacy noise on matching quality.
Repeated observations help distinguish participants with similar cognitive trajectories from those who merely look similar at one visit. The Alzheimer's work investigates progression from mild cognitive impairment and the value of temporal information for finding research peers.
Cognitive assessments, MRI, PET, genetics, and cerebrospinal fluid biomarkers provide different views of Alzheimer's disease. Learned fusion is evaluated against simpler combinations to study which inputs support useful patient similarity.
Alzheimer's research visits do not always include every assessment or scan. Missing-input experiments examine how patient representations and matching change when some of the available research data types are absent.
ADNI provides the primary longitudinal setting. Comparisons with ROSMAP examine representation transfer within Alzheimer's and aging research, where measurements and participant populations differ. Research-cohort transfer is distinct from prospective clinical validation.
The Alzheimer's work studies whether incorporating observations from another site changes previously learned patient relationships. Retaining earlier structure and monitoring shifts in the research population remain ongoing evaluation questions.
Longitudinal cognitive change, incomplete visits, and differences between research cohorts shape how we evaluate patient similarity.
Patient matching depends on how well the representation captures Alzheimer's-related clinical structure. Privacy methods, temporal matching, and input fusion must be assessed against that foundation.
A single assessment cannot describe an entire trajectory. Repeated cognitive measurements and visit timing help frame the question of which research participants are progressing in similar ways.
Cognitive tests, imaging, genetics, and biomarkers should not be treated as interchangeable signals. Their contribution to Alzheimer's patient similarity needs to be measured for the specific research task.
Incomplete visits are part of longitudinal Alzheimer's research. Evaluate matching with the inputs actually available, and distinguish measured observations from any estimated values.
Results depend on the cohort, available measurements, and evaluation setup. A promising retrospective Alzheimer's result is a reason for further study, not a substitute for independent or prospective evaluation.
The Alzheimer's research pipeline maps cognitive assessments, imaging, genetics, and biomarkers into representations for similarity analysis. Source records and the representations used for matching have separate privacy requirements.
In the Alzheimer's research configuration, cognitive scores, MRI, PET, genetic inputs, and cerebrospinal fluid biomarkers are encoded into a shared 64-dimensional representation. Similarity and temporal information support research matching; privacy controls govern what a participating site may share.
In the research architecture, site nodes prepare representations locally and the Soma Core compares Alzheimer's trajectories. The diagram and simulation illustrate the design; they do not show a live hospital network.
Research-site nodes prepare Alzheimer's patient representations from locally held assessments, imaging, genetics, and biomarkers. The architecture separates source records from the representations used for matching.
The core studies similarity and cognitive trajectories within Alzheimer's research. It brings together representations and temporal information to identify comparable research participants.
The onboarding protocol is designed to calibrate representations from another research site before matching. Access, compatibility, and privacy controls remain part of the evaluation.
Alzheimer's experiments examine protected population summaries, privacy budgets, and their effect on similarity. Representations require privacy safeguards even when source records remain local.
ADNI provides the primary longitudinal research setting. ROSMAP provides a comparison within Alzheimer's and aging research. These cohorts support research evaluation, not a claim of a deployed clinical network.
Alzheimer's Disease Neuroimaging Initiative data supports longitudinal research using cognitive assessments, brain MRI, genetics, cerebrospinal fluid biomarkers, and PET imaging.
ROSMAP provides an Alzheimer's and aging research comparison setting, including brain tissue gene-expression measurements. Different measurements and populations require a separate interpretation of transfer results.
The next steps stay focused on Alzheimer's disease: stronger longitudinal evaluation, independent research partnerships, and a clearer understanding of performance over time.
Expand the assessment of cognitive trajectories, participant subgroups, and incomplete visits within the Alzheimer’s research scope.
Explore independent evaluation with Alzheimer’s researchers, including site-specific data permissions, cohort compatibility, and prospective study design.
Study how changes in visit schedules, measurements, and research populations affect the stability of Alzheimer’s patient matching over time.
SOMA is the Alzheimer's research initiative of Curadai — a company building AI infrastructure for non-profit and healthcare institutions. Contact us to discuss Alzheimer's research collaboration, longitudinal data, or evaluation of federated patient similarity.